skip to Main Content

Led by Former Lilly Exec, Apexian Out to Tackle Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Pancreatic cancer’s standard of care includes a drug that does not help most people diagnosed with the disease. Gemcitabine (Gemzar) works in only about 10 percent of patients, says Steve Carchedi, CEO of Apexian Pharmaceuticals.

Carchedi knows about gemcitabine’s limitations because he worked at Eli Lilly (NYSE: LLY) when the FDA approved the Indianapolis-based company’s drug in 1996 to treat pancreatic cancer. Read more . . .

Back To Top